The PsyPal project addresses the profound psychological and existential distress experienced by patients in palliative care with illnesses like COPD, ALS, MS, and Atypical Parkinsonian Disorders, for whom current treatments are often inadequate. We are investigating psilocybin therapy as a novel approach to alleviate this suffering. The project's central objective is a rigorous, multi-centre clinical trial across four EU countries to evaluate the safety and effectiveness of a standardized, patient-centered psilocybin therapy.
In its first 18 months, PsyPal established the complete foundation for this trial, securing full regulatory and ethical approval in the Netherlands, Denmark, Portugal, and the Czech Republic. A comprehensive therapy manual was developed, therapists were trained to a consistent standard, and key infrastructure—including study drug delivery, a digital care platform, and peer-support networks—is in place. Beyond evaluating clinical value, the project seeks to understand the therapy's mechanisms by analyzing biological and psychological data to identify predictive markers for patient response. Ultimately, PsyPal aims to pave the way for the ethical, cost-effective, and sustainable integration of psilocybin therapy into European palliative care, improving quality of life for patients and their families.
Beyond the clinical trial, PsyPal is dedicated to creating a sustainable framework for the future. This includes developing a model for continued care with peer-support networks and a digital platform to support patients and their families after the treatment period. By engaging with patients, policymakers, and healthcare stakeholders from the outset, the project aims to pave the way for the ethical and cost-effective integration of this novel therapy into European healthcare systems, ultimately offering a new path to alleviate suffering and improve the quality of life for those in palliative care.
